New data shows Seroquel achieves remission in bipolar mania
AstraZeneca announced important modern data today that show patients with bipolar disorder who were treated with SEROQUEL (quetiapine) were significantly more favoured to achieve unqualified lessening of their mania symptoms compared to patients who received placebo.1 The data were presented at the 157th American Psychiatric Association (APA) congress.
After 3 weeks of treatment with SEROQUEL monotherapy (median dose of 600mg/day), 36% of patients had achieved remission from their symptoms compared to 21.5% of patients treated with placebo (p